Rezolute, Inc. (RZLT)
4.58
+0.04
(+0.88%)
USD |
NASDAQ |
Sep 04, 16:00
4.575
0.00 (0.00%)
After-Hours: 20:00
Rezolute Research and Development Expense (Quarterly) : 11.41M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 11.41M |
| December 31, 2025 | 14.35M |
| September 30, 2025 | 13.15M |
| June 30, 2025 | 20.86M |
| March 31, 2025 | 15.28M |
| December 31, 2024 | 12.63M |
| September 30, 2024 | 12.75M |
| June 30, 2024 | 19.09M |
| March 31, 2024 | 12.40M |
| December 31, 2023 | 12.04M |
| September 30, 2023 | 12.21M |
| June 30, 2023 | 10.93M |
| March 31, 2023 | 14.23M |
| December 31, 2022 | 10.94M |
| September 30, 2022 | 7.704M |
| June 30, 2022 | 8.574M |
| March 31, 2022 | 8.686M |
| December 31, 2021 | 9.452M |
| September 30, 2021 | 5.774M |
| June 30, 2021 | 4.389M |
| March 31, 2021 | 3.758M |
| December 31, 2020 | 4.496M |
| September 30, 2020 | 2.344M |
| June 30, 2020 | 2.445M |
| March 31, 2020 | 3.733M |
| Date | Value |
|---|---|
| December 31, 2019 | 5.038M |
| September 30, 2019 | 3.234M |
| June 30, 2019 | 1.718M |
| March 31, 2019 | 15.12M |
| December 31, 2018 | 1.309M |
| September 30, 2018 | 0.9299M |
| June 30, 2018 | 7.060M |
| March 31, 2018 | 2.496M |
| December 31, 2017 | 3.413M |
| September 30, 2017 | 4.311M |
| June 30, 2017 | 3.094M |
| March 31, 2017 | 3.439M |
| December 31, 2016 | 3.075M |
| September 30, 2016 | 2.486M |
| June 30, 2016 | 2.646M |
| March 31, 2016 | 2.310M |
| December 31, 2015 | 2.524M |
| September 30, 2015 | 1.968M |
| June 30, 2015 | 1.732M |
| March 31, 2015 | 1.291M |
| December 31, 2014 | 1.566M |
| September 30, 2014 | 0.1126M |
| June 30, 2014 | 0.0321M |
| March 31, 2014 | 0.0022M |
| December 31, 2013 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| SELLAS Life Sciences Group, Inc. | 6.272M |
| AbbVie, Inc. | 2.344B |
| Marker Therapeutics, Inc. | 1.476M |
| Avalo Therapeutics, Inc. | 23.42M |
| Krystal Biotech, Inc. | 13.16M |